MCM
ELDN icon

MAI Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

MAI Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-133
Closed -$410 – 2825
2026
Q1 		$410 Buy
+133
New +$313 ﹤0.01% 4463

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

MAI Capital Management's ELDN Position: Q2 2026 in Review

MAI Capital Management sold out of Eledon Pharmaceuticals (ELDN) in Q2 2026, closing a stake of 133 shares — an estimated $410 sold.

MAI Capital Management first reported a position in ELDN in Q1 2026 and held it in 1 quarter. The position peaked at $410 in Q1 2026. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • MAI Capital Management reported no remaining Eledon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 133 Eledon Pharmaceuticals shares in Q2 2026, an estimated $410.
  • MAI Capital Management first reported a position in Eledon Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's Eledon Pharmaceuticals position peaked at $410 in Q1 2026.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.